<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02806128</url>
  </required_header>
  <id_info>
    <org_study_id>MAISKFE1.0</org_study_id>
    <nct_id>NCT02806128</nct_id>
  </id_info>
  <brief_title>The Metabolism Research of KLK Treating Acute Cerebral Ischemic Stroke: Focus on Drug Frequency-Efficacy Relationship</brief_title>
  <acronym>MAISKFE</acronym>
  <official_title>The Metabolism Research of KLK Treating Acute Cerebral Ischemic Stroke: Focus on Drug Frequency-Efficacy Relationship</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huisheng Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effectiveness of the of kallikrein in the different drug frequency for acute
      anterior circulation cerebral infarction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the decrease of National Institute of Health stroke scale(NIHSS)</measure>
    <time_frame>14 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Barthel Index</measure>
    <time_frame>90 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Modified Rankin Scale</measure>
    <time_frame>90 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of the National Institute of Health stroke scale</measure>
    <time_frame>8 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the composite of ischemic vascular events</measure>
    <time_frame>90 Days</time_frame>
    <description>ischemic stroke, MI, or ischemic vascular death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of Human Urinary Kallidinogenase for Injection (KLK) three times a day, 14 days .
Patients need to complete laboratory tests within a specified time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of Human Urinary Kallidinogenase for Injection (KLK) Once times a day, 14 days .
Patients need to complete laboratory tests within a specified time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Urinary Kallidinogenase for Injection</intervention_name>
    <description>Patients need to complete laboratory tests within a specified time and to complete the experimental requirements of medication time</description>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>KLK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 80 years old;

          2. First time diagnosed or have history of acute anterior circulation cerebral infarction
             without serious sequelae (mRS = 0-2);

          3. Acute anterior circulation cerebral infarction with large artery atherosclerotic
             etiology;

          4. Ability to randomize within 48 h of time last known free of new ischemic symptoms.

          5. National Institute of Health stroke scale(NIHSS) ranges from 7 to 22;

          6. signed written informed consent.

        Exclusion Criteria:

          1. Cerebral CT shows cerebral hemorrhage disease: cerebral hemorrhage, subarachnoid
             hemorrhage, etc.;

          2. Transient ischemic attack;

          3. Serious disturbance of consciousness: Glasgow Coma ScaleGCS（GCS）≤8;

          4. Combined angiotensin-converting enzyme inhibitor(ACEI) less than 5 half-time
             (according to its instruction), or need to be treated with ACEI;

          5. Past or present suffering from hemorrhagic tendency of the disease;

          6. The investigator in consideration of the other condition that the patients doesn't fit
             to participate in this clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huisheng Chen</last_name>
    <role>Study Chair</role>
    <affiliation>General Hospital of Shenyang Military Region</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huisheng Chen</last_name>
    <phone>86-24-28897511</phone>
    <email>chszh@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>zhonghe Zhou</last_name>
    <phone>86-24-28897511</phone>
    <email>Zhouz.h@tom.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General hospital of shenyang military region</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110840</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hou Xiaowen, Master</last_name>
      <phone>862428897511</phone>
      <phone_ext>15840240196</phone_ext>
      <email>sophia_hxw@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Xia CF, Yin H, Borlongan CV, Chao L, Chao J. Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension. 2004 Feb;43(2):452-9. Epub 2003 Dec 29.</citation>
    <PMID>14698996</PMID>
  </reference>
  <reference>
    <citation>Xia CF, Smith RS Jr, Shen B, Yang ZR, Borlongan CV, Chao L, Chao J. Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension. 2006 Apr;47(4):752-61. Epub 2006 Mar 13.</citation>
    <PMID>16534002</PMID>
  </reference>
  <reference>
    <citation>Xia CF, Yin H, Yao YY, Borlongan CV, Chao L, Chao J. Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum Gene Ther. 2006 Feb;17(2):206-19.</citation>
    <PMID>16454654</PMID>
  </reference>
  <reference>
    <citation>Chen ZB, Huang DQ, Niu FN, Zhang X, Li EG, Xu Y. Human urinary kallidinogenase suppresses cerebral inflammation in experimental stroke and downregulates nuclear factor-kappaB. J Cereb Blood Flow Metab. 2010 Jul;30(7):1356-65. doi: 10.1038/jcbfm.2010.19. Epub 2010 Feb 24.</citation>
    <PMID>20179726</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2016</study_first_submitted>
  <study_first_submitted_qc>June 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2016</study_first_posted>
  <last_update_submitted>January 5, 2017</last_update_submitted>
  <last_update_submitted_qc>January 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Huisheng Chen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cerebral infarction</keyword>
  <keyword>kallikrein</keyword>
  <keyword>KLK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kallikreins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the completion of clinical trials ，Through the article published and upload data 。</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

